Ben’s List 58

Most startup founders treat events like they’re going travelling: count the days, block the calendar, done. But event tickets don’t come cheap, and the actual affair can eat into your budget in so many different ways, you’ll be left with a hole in your company wallet. You see, the problem here is a simple case of math: one can’t budget for unforeseen expenses. That’s why we’ve put together a simple formula that founders can tweak to suit their business needs. The 2:1 rule nobody talks about Here’s a simple rule: Every single day at an event requires two full days of preparation. This isn’t bureaucratic overhead, it’s the operational reality of doing events properly. Why does this ratio work? Because events operate on a timeline that’s fundamentally incompatible with how startups work. Most conferences lock speaker slots, booth spaces, and partnership opportunities months in advance. You can’t A/B test them or sprint your way in at the last minute. Scaleups and corporates have dedicated field marketing teams who start preparing months in advance for events. They’ve already mapped the venue, scheduled meetings, and briefed their booth staff. If you show up with two hours of prep, you’re invisible. But why should you set aside two days for every event day? You’ll fill them with research, targeting, outreach, scheduling, content, positioning, logistics operations, internal coordination, and post-event planning.  You can’t change your pitch deck the morning of your panel. Events punish improvisation because the stakes are live and all opportunity windows close fast. That’s why a 2:1 ratio is the minimum buffer you need to make showing up worthwhile. A three-day conference isn’t a three-day commitment; you’ll have to set aside at least six days before factoring in travel, team coordination, or what you’ll actually do at the event. Treat it as the baseline for local events that you’re only attending, too. And when you add distance, team members or booth logistics to the equation, that number explodes. The winning formula Here’s what no event organizer will tell you upfront: Total Time = (Event Days × 2) × Distance Factor × Team Factor × Activity Factor Distance multipliers Team size factors Activity type factors What does it look like in the real world? Let’s run an example scenario: Say you’re exhibiting at Web Summit with two co-founders. Calculation: (3 days × 2) × 1.5 (international) × 1.3 (team of three) × 1.5 (exhibiting) = 17.6 days That’s nearly four working weeks of founder time. Not calendar days — productive working days. An entire sprint. A fundraising cycle. A product release window. That’s before you account for the inevitable chaos: marketing materials might get delayed, or your booth might require a last-minute redesign, or one of your team might fall ill on day two. This matters more than you think Startups don’t fail because they attend too many events. They fail because they attended the wrong events and didn’t realize the true cost until it was too late. Most early-stage founders operate on razor-thin runways and even thinner margins. Losing 17 days to the wrong conference can mean missing a critical hiring window, pushing a launch back by a quarter, or running out of cash. The opportunity cost is immense. Three filters to help you decide Preparation is table stakes, but the real competitive advantage is selection. Before you commit to any event, run it through these three filters: 1. Are your top 10 target customers actually attending? Don’t settle for “the industry will be there,” or “it’s a great brand.” Will the specific people who can write cheques or sign contracts be in the venue? If you can’t name at least five confirmed attendees you want to meet, you’re engaging in speculation, and speculation is expensive. 2. Can you get time with decision makers? Networking is not the same as dealmaking. Conferences are full of people collecting business cards and having “great chats” that go nowhere. Look for pre-scheduled meetings, private roundtables, investor office hours, or curated dinners. If the event doesn’t facilitate structured access, you’re paying to work a room. 3. Does the timing align with your fundraising or launch cycle? Attending a major event two weeks before a funding deadline is fundraising malpractice. Exhibiting at a trade show when your product isn’t ready to demo is theatre, not business development. Timing isn’t everything, but mistimed events have the potential to burn capital and credibility in equal measure. The real decision Preparation is hard, but preparing brilliantly for the wrong event isn’t going to yield the results you’re looking for. The formula above isn’t meant to scare founders away from conferences. If you’re going to invest 17 days of founder time, you’d better know exactly what ROI you’re chasing and have a plan to capture it. Most founders wing it. The folks who don’t tend to be the ones still standing when funding dries up. At Sesamers, we’ve spent years inside the event ecosystem, watching startups burn time and capital on conferences that looked good on paper but delivered nothing. The startups that survive and thrive aren’t the ones who attended the most events; they simply skipped those that weren’t relevant, and attended the right events at the right time, with the right preparation. So before you book your next booth or confirm that speaking slot, do the math, and see if you can afford to go wrong.

The ambient energy harvesting sector is experiencing unprecedented momentum across Europe as industries seek sustainable alternatives to traditional battery systems. French innovator Dracula Technologies has captured €30 million in its Series A extension round, positioning the company to accelerate the industrial rollout of its photovoltaic solutions that generate electricity from indoor ambient light. This substantial funding milestone reflects growing investor confidence in energy harvesting technologies that can power IoT devices indefinitely without battery replacement. The round’s completion signals a maturing European cleantech ecosystem where strategic capital allocation increasingly favours practical sustainability solutions over theoretical breakthroughs. Ambient energy funding attracts strategic European backing Banque des Territoires, France’s public investment bank, led this Series A extension, demonstrating how European institutional capital is backing the region’s transition to autonomous energy systems. The investor’s participation aligns with France’s broader industrial strategy to reduce dependence on imported battery technologies whilst strengthening domestic manufacturing capabilities. “Dracula Technologies represents exactly the kind of deep-tech innovation that positions Europe at the forefront of the energy transition,” noted a spokesperson from Banque des Territoires. “Their ability to transform any light source into sustainable power addresses critical industrial challenges whilst reducing environmental impact.” The funding round’s structure reflects sophisticated European venture dynamics, where public-private partnerships increasingly drive strategic technology development. This approach contrasts sharply with Silicon Valley’s purely private capital model, offering European startups patient capital aligned with long-term industrial objectives rather than rapid exits. Industrial IoT applications drive market expansion Dracula Technologies’ photovoltaic solutions target the exploding European IoT market, where battery replacement costs and environmental concerns create significant operational challenges. Their technology enables sensors, smart meters, and monitoring devices to operate autonomously in warehouses, factories, and urban environments using nothing more than ambient artificial lighting. The company’s go-to-market strategy focuses on European industrial clients seeking to reduce maintenance costs whilst meeting increasingly stringent sustainability regulations. Their solutions particularly resonate with manufacturers operating across fragmented European markets, where standardised power solutions can dramatically reduce operational complexity. “We’re not just replacing batteries; we’re eliminating an entire category of industrial maintenance whilst enabling truly sustainable IoT deployments,” explained Dracula Technologies’ leadership. “This funding allows us to scale production and accelerate our expansion across European industrial hubs.” The €30 million will primarily fund manufacturing capacity expansion and product development, enabling the company to meet growing demand from automotive, logistics, and smart building sectors. This capital deployment strategy reflects European startups’ characteristic focus on sustainable growth over aggressive market expansion. As European regulations increasingly mandate energy efficiency and sustainability reporting, ambient energy harvesting technologies like Dracula’s position the continent’s industries to meet these requirements whilst reducing operational costs. This Series A extension signals that strategic investors recognise the massive potential of turning every indoor environment into a distributed power grid.

Europe’s biotechnology sector is witnessing unprecedented investment in manufacturing innovation, with Swedish companies leading the charge in making advanced therapies accessible worldwide. The latest milestone comes from Cellcolabs, which has secured €10.3 million in funding to democratise stem cell manufacturing through scalable automation technology that promises to reduce costs by 90%. This significant investment round positions Sweden at the forefront of the global cell therapy manufacturing revolution, addressing one of the most pressing bottlenecks in regenerative medicine – the prohibitive cost of producing therapeutic cells at scale. Stem cell manufacturing funding attracts strategic European investors The €10.3 million round was led by Titian Capital, a venture firm with deep expertise in European life sciences investments. The funding demonstrates growing investor confidence in manufacturing-focused biotechnology solutions, particularly those that can bridge the gap between laboratory breakthroughs and patient access. “Cellcolabs represents exactly the kind of European innovation we’re looking for – deep technical expertise combined with a clear path to global impact,” noted a partner at Titian Capital. “Their automated manufacturing platform addresses a fundamental constraint in the cell therapy industry, where manual processes have kept treatments expensive and limited in scale.” The investment aligns with broader European Union initiatives to strengthen the continent’s position in advanced therapy manufacturing, including the EU’s €1 billion investment in health technology infrastructure announced earlier this year. European investors are increasingly recognising the strategic importance of controlling critical manufacturing capabilities rather than relying on overseas production. Automated cell therapy production targets European expansion Founded as a spin-off from Sweden’s renowned Karolinska Institute, Cellcolabs has developed proprietary automation technology that transforms how stem cells and other therapeutic cells are manufactured. Their platform replaces labour-intensive manual processes with automated systems that maintain the precise environmental control required for cell therapy production. “We’re not just reducing costs – we’re reimagining how cell therapies can be manufactured at the scale needed to treat millions of patients rather than thousands,” explained the company’s CEO. “European regulatory frameworks actually provide us with advantages here, as our quality systems are designed from the ground up to meet the highest standards.” The funding will accelerate Cellcolabs’ European expansion, with plans to establish manufacturing partnerships across key markets including Germany, France, and the Netherlands. The company is particularly well-positioned to benefit from the European Medicines Agency’s streamlined approval processes for advanced therapy medicinal products, which favour companies with robust manufacturing documentation. Unlike many biotech companies that focus primarily on drug discovery, Cellcolabs addresses the manufacturing bottleneck that has limited the commercialisation of promising cell therapies across Europe. This €10.3 million investment signals a maturing European biotech ecosystem where manufacturing innovation receives the same attention as scientific breakthroughs. For Swedish life sciences, it reinforces the country’s position as a global leader in translating academic research into scalable healthcare solutions.